neurogenic detrusor overactivity
Urology · 2012–2012
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| botulinum toxin type A Treatment of urinary incontinence due to neurogenic detrusor overactivity in patients who are not adequately managed by anti-cholinergic medication. | Jul 2012 | Recommended with restriction | unclear |
| botulinum toxin type A Treatment of urinary incontinence due to neurogenic detrusor overactivity in patients who are not adequately managed by anti-cholinergic medication. | Jul 2012 | Recommended with restriction | unclear |
What the PBS pays
$73M in government benefit over 2024–25, across 140,782 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| botulinum toxin type A | $72.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| oxybutynin hydrochlorideOxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal) | TA1154 | terminated | 2026-05 |
| mirabegronMirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) | TA1100 | terminated | 2025-10 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.